Surmodics Reports Fourth Quarter Fiscal 2018 Results and Issues Fiscal 2019 Guidance

November 9, 2018 at 7:30 AM EST
PDF Version

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Nov. 9, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 fourth quarter ended September 30, 2018, and provided its financial outlook for fiscal 2019.

Summary of Fourth Quarter Fiscal 2018 Highlights and Fiscal 2019 Guidance

  • Revenue of $23.0 million, an increase of 15% year-over-year
  • GAAP EPS of ($0.13), non-GAAP EPS of $0.05
  • Submitted application for first in-human study for arteriovenous (AV) access drug coated balloon (DCB)
  • Fiscal 2019 revenue outlook of $92.0 to $97.0 million, GAAP EPS outlook of ($0.32) to ($0.02)

“We continue to drive strong revenue growth and solid operational performance as we execute on our strategic objectives,” said Gary Maharaj, President & CEO of Surmodics. “The positive twelve-month data recently presented from PREVEIL, the early feasibility study of our SurVeil® DCB and the recent submission for first in-human study for our AV access DCB, AVess™, demonstrate meaningful progress towards our whole-products solutions initiatives.”

Fourth Quarter Fiscal 2018 Financial Results
Total revenue for the fourth quarter of fiscal 2018 was $23.0 million, as compared with $20.1 million in the prior-year period. Medical Device revenue was $17.0 million in the fourth quarter of fiscal 2018, as compared with $14.7 million in the year-ago period, an increase of 15.4%, and includes $2.2 million from our SurVeil agreement with Abbott. In Vitro Diagnostics revenue was $6.1 million for the fourth quarter of fiscal 2018 as compared with $5.3 million in the same prior-year quarter, an increase of 13.4%.

Diluted GAAP loss per share in the fourth quarter of fiscal 2018 was $(0.13) as compared with diluted GAAP earnings per share of $0.03 in the year-ago period. On a non-GAAP basis, earnings per share were $0.05 in the fourth quarter of fiscal 2018, as compared with $0.18 in the year-ago period.

As of September 30, 2018, cash and investments were $65.0 million. Surmodics generated cash from operating activities of $34.1 million in fiscal 2018. Capital expenditures totaled $9.0 million for fiscal 2018.

Fiscal 2019 Outlook
Surmodics expects fiscal year 2019 revenue to range from $92 million to $97 million. The Company expects diluted EPS in the range of ($0.32) to ($0.02) per share, which reflects the Company’s continued investment in research and development to further its whole-product solutions strategy. Non-GAAP diluted EPS is expected to be in the range of ($0.07) to $0.23 per share.

Conference Call
Surmodics will host a webcast at 7:30 a.m. CT (8:30 a.m. ET) today to discuss fourth quarter results. To access the webcast, go to the investor relations portion of the Company’s website at https://surmodics.gcs-web.com and click on the webcast icon. The webcast will be archived on the Company’s website for 90 days. A replay of the fourth quarter conference call will be available by dialing 888-203-1112 and entering conference call ID passcode 1123199. The audio replay will be available beginning at 10:30 a.m. CT on Friday, November 9, 2018, until 10:30 a.m. CT on Friday, November 16, 2018.

About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address unmet clinical needs for its medical device customers and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.

Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations regarding the Company’s performance in the near- and long-term, including our revenue and earnings expectations for fiscal 2019, and our SurVeil DCB and other proprietary products are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including (1) our ability to successfully develop, obtain regulatory approval for, and commercialize our SurVeil DCB (including realization of the full potential benefits of our agreement with Abbott), and other proprietary products; (2) our reliance on third parties (including our customers and licensees) and their failure to successfully develop, obtain regulatory approval for, market and sell products incorporating our technologies; (3) possible adverse market conditions and possible adverse impacts on our cash flows, and (4) the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2017, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at https://surmodics.gcs-web.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

Use of Non-GAAP Financial Information
In addition to reporting financial results in accordance with U.S. generally accepted accounting principles, or GAAP, Surmodics is reporting non-GAAP financial results including EBITDA and Adjusted EBITDA, non-GAAP operating (loss) income, non-GAAP income before income taxes, non-GAAP net income, and non-GAAP diluted earnings per share, and the non-GAAP effective income tax rate. We believe that these non-GAAP measures, when read in conjunction with the Company’s GAAP financial statements, provide meaningful insight into our operating performance excluding certain event-specific matters, and provide an alternative perspective of our results of operations. We use non-GAAP measures, including those set forth in this release, to assess our operating performance and to determine payout under our executive compensation programs. We believe that presentation of certain non-GAAP measures allows investors to review our results of operations from the same perspective as management and our board of directors and facilitates comparisons of our current results of operations. The method we use to produce non-GAAP results is not in accordance with GAAP and may differ from the methods used by other companies. Non-GAAP results should not be regarded as a substitute for corresponding GAAP measures but instead should be utilized as a supplemental measure of operating performance in evaluating our business. Non-GAAP measures do have limitations in that they do not reflect certain items that may have a material impact on our reported financial results. As such, these non-GAAP measures should be viewed in conjunction with both our financial statements prepared in accordance with GAAP and the reconciliation of the supplemental non-GAAP financial measures to the comparable GAAP results provided for the specific periods presented, which are attached to this release.

   

Surmodics, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(Unaudited)

 
Three Months Ended Years Ended
September 30, September 30,
2018   2017 2018   2017
(Unaudited) (Unaudited)
Revenue:
Product sales $ 10,704 $ 8,826 $ 37,953 $ 32,790
Royalties and license fees 10,323 9,223 35,424 31,787
Research, development and other   2,011   2,009   7,959   8,535
Total revenue   23,038   20,058   81,336   73,112
Operating costs and expenses:
Product costs 4,089 3,317 13,997 11,422
Research and development 12,591 9,713 40,973 31,817
Selling, general and administrative 6,505 5,307 24,111 20,478
Acquired in-process research and development — — 7,888 —
Acquired intangible asset amortization 613 629 2,491 2,419
Contingent consideration expense (gain)   1,681   676   675   (127 )
Total operating costs and expenses   25,479     19,642   90,135   66,009
Operating (loss) income (2,441 ) 416 (8,799 ) 7,103
Other income (loss), net   411   (224 )   1,267   (70 )
(Loss) income from operations before income taxes (2,030 ) 192 (7,532 ) 7,033
Income tax benefit (provision)   277   208   3,075

 

(3,107 )
Net (loss) income $ (1,753 ) $ 400 $ (4,457 ) $ 3,926
 
Basic (loss) income per share: $ (0.13 ) $ 0.03 $ (0.34 ) $ 0.30
 
Diluted (loss) income per share: $ (0.13 ) $ 0.03 $ (0.34 ) $ 0.29
 
Weighted average number of shares outstanding:
Basic 13,279 13,041 13,157 13,153
Diluted 13,279 13,365 13,157 13,389
 

 

Surmodics, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands)
(Unaudited)

 
September 30,
2018   2017
Assets (Unaudited)
Current Assets:
Cash and cash equivalents $ 23,318 $ 16,534
Restricted cash 350 —
Available-for-sale securities 41,352 31,802
Accounts receivable, net 8,877 7,211
Inventories, net 4,016 3,516
Prepaids and other   3,614   1,820
Total Current Assets 81,527 60,883
Property and equipment, net 30,143 22,942
Deferred tax assets 6,304 4,027
Intangible assets, net 17,683 20,562
Goodwill 27,032 27,282
Other assets   1,446   897
Total Assets $ 164,135 $ 136,593
Liabilities and Stockholders’ Equity
Current Liabilities:
Contingent consideration, current portion 11,041 1,750
Deferred revenue 9,646 62
Other current liabilities   14,446   7,991
Total Current Liabilities 35,133 9,803
Contingent consideration, less current portion 3,425 13,114
Deferred revenue 11,247 181
Other long-term liabilities   5,720   1,938
Total Liabilities 55,525 25,036
Total Stockholders’ Equity   108,610   111,557
Total Liabilities and Stockholders’ Equity $ 164,135 $ 136,593
 

   

Surmodics, Inc. and Subsidiaries
Supplemental Segment Information
(in thousands)
(Unaudited)

 
Three Months Ended September 30
2018   2017
Revenue:   % of Total   % of Total

%
Change
Medical Device $ 16,986 73.7% $ 14,723

73.4%

 

15.4%
In Vitro Diagnostics   6,052 26.3%   5,335

26.6%

 

13.4%
Total revenue $ 23,038 $ 20,058 14.9%
 
Years Ended September 30,
2018 2017
Revenue: % of Total % of Total

%
Change
Medical Device $ 60,513 74.4% $ 53,983

73.8%

 

12.1%
In Vitro Diagnostics   20,823

25.6%

 

  19,129

26.2%

 

8.9%
Total revenue $ 81,336 $ 73,112 11.2%
 
Three Months Ended

Years Ended
September 30, September 30,
2018 2017 2018 2017
Operating (loss) income:
Medical Device $ (2,127 ) $ 276 $ (8,478 ) $ 6,902
In Vitro Diagnostics   2,350   2,371   8,619   8,293
Total segment operating income 223 2,647 141 15,195
Corporate   (2,664 )   (2,231 )   (8,940 )   (8,092 )
Total (loss) income from operations $ (2,441 ) $ 416 $ (8,799 ) $ 7,103
 

   

Surmodics, Inc. and Subsidiaries
Reconciliation of GAAP Measures to Non-GAAP Amounts
Schedule of EBITDA, Adjusted EBITDA and Cash Flows from Operations
(in thousands)
(Unaudited)

 
Three Months Ended Years Ended
September 30, September 30,
2018   2017 2018   2017
Net (loss) income $ (1,753 ) $ 400 $ (4,457 ) $ 3,926
Income tax (benefit) provision (277 ) (208 ) (3,075 ) 3,107
Depreciation and amortization 1,720 1,549 6,431 5,555
Investment income, net   (285 )   (116 )   (851 )   (390 )
EBITDA   (595 )   1,625   (1,952 )   12,198
 
Adjustments:
Contingent consideration expense (gain) (1) 1,681 676 675 (127 )
Foreign exchange (gain) loss (2) (74 ) 347 (148 ) 474
Gain on strategic investment (4) — (43 ) (177 ) (43 )
Claim settlement accrual (6) — — 1,000 —
Acquired in-process research and development (7) — — 7,888 —
Asset impairment (8)   —   427   —   427
Adjusted EBITDA $ 1,012 $ 3,032 $ 7,286 $ 12,929
 
 
Net Cash Provided by Operating Activities $ 4,830 $ 6,397 $ 34,052 $ 14,053
 
 

Estimated Non-GAAP Net Earnings per Common Share Guidance Reconciliation
For the Fiscal Year Ended September 30, 2019
(Unaudited)

 
Fiscal 2019 Full-Year Estimate
Low   High
GAAP results $ (0.32 ) $ (0.02 )
Contingent consideration adjustments (1) 0.08 0.08
Amortization of acquired intangibles (3)   0.17   0.17
Non-GAAP results $ (0.07 ) $ 0.23
 

 

Surmodics, Inc., and Subsidiaries
Net Income (Loss) and Diluted EPS (LPS) GAAP to Non-GAAP Reconciliation
 (in thousands, except per share data)
(Unaudited)

 
For the Three Months Ended September 30, 2018

Total
Revenue

    

Operating
(Loss)
Income

  

Operating
(Loss) Income
Percentage

    

(Loss) Income
Before
Income Taxes

  

Net
(Loss)
Income (10)

  

Diluted
EPS

  

Effective
tax rate
GAAP $ 23,038 $ (2,441 ) (10.6 )% $ (2,030 ) $ (1,753 ) $ (0.13 ) 13.6 %
Adjustments:
Contingent consideration expense (1) ― 1,681 7.3 1,681 1,681 0.13
Foreign exchange gain (2) ― — — (74 ) (74 ) (0.01 )
Amortization of acquired intangible assets (3) ― 613 2.7 613 561 0.04
Tax reform impact (5) ― — — — 327 0.02
Dilutive effect of outstanding stock awards (9) ―   — —   —   —   (0.01 )  
Non-GAAP $ 23,038 $ (147 ) (0.6 )% $ 190 $ 742 $ 0.05 (290.5 )%
 
For the Three Months Ended September 30, 2017

Total
Revenue

Operating
Income

Operating
Income
Percentage

Income Before
Income Taxes

Net
Income
(10)

Diluted
EPS

Effective
tax rate
GAAP $ 20,058 $ 416 2.1 % $ 192 $ 400 $ 0.03 (108.3 )%
Adjustments:
Contingent consideration expense (1) ― 676 3.4 676 676 0.05
Foreign exchange loss (2) ― — — 347 347 0.03
Amortization of acquired intangible assets (3) ― 629 3.1 629 550 0.04
Gain on strategic investment (4) ― — —

(43

)

(43

)

(0.00

)
Asset impairment (8) ―   427 2.1   427   427   0.03  
Non-GAAP $ 20,058 $ 2,148 10.7 % $ 2,228 $ 2,357 $ 0.18 (5.8 )%
 

 
For the Year Ended September 30, 2018

Total
Revenue

  

Operating
(Loss)
Income

  

Operating
(Loss) Income
Percentage

  

(Loss) Income
Before
Income Taxes

  

Net
(Loss)
Income (10)

  

Diluted
EPS

  

Effective
tax rate
GAAP $ 81,336 $ (8,799 ) (10.8 )% $ (7,532 ) $ (4,457 ) $ (0.34 ) 40.8 %
Adjustments:
Contingent consideration expense (1) ― 675 0.8 675 675 0.05
Foreign exchange gain (2) ― — — (148 ) (148 ) (0.01 )
Amortization of acquired intangible assets (3) ― 2,491 3.1 2,491 2,282 0.17
Gain on strategic investment (4) ― — — (177 ) (177 )

(0.01

)

Tax reform impact (5) ― — — — 1,573 0.12
Claim settlement accrual (6) ― 1,000 1.2 1,000 755 0.06

Acquired in-process research and development (7)

― 7,888 9.7 7,888 6,232 0.47
Dilutive effect of outstanding stock awards (9) ―   — —   —   —   (0.02 )  
Non-GAAP $ 81,336 $ 3,255 4.0 % $ 4,197 $ 6,735 $ 0.49 (60.5 )%
 
For the Year Ended September 30, 2017

Total
Revenue

Operating
Income

Operating
Income
Percentage

Income
Before
Income Taxes

Net
Income
(10)

Diluted
EPS

Effective
tax rate
GAAP $ 73,112 $ 7,103 9.7 % $ 7,033 $ 3,926 $ 0.29 44.2 %
Adjustments:
Contingent consideration gain (1) ― (127 ) (0.2 ) (127 ) (127 ) (0.01 )
Foreign exchange loss (2) ― — — 474 474 0.04
Amortization of acquired intangible assets (3) — 2,419 3.3 2,419 2,105 0.16
Gain on strategic investment (4) ― — — (43 ) (43 ) (0.00 )
Asset impairment (8) ―   427 0.6   427   427   0.03  
Non-GAAP $ 73,112 $ 9,822 13.4 % $ 10,183 $ 6,762 $ 0.51 33.6 %
 
(1)   Represents accounting adjustments to state acquisition-related contingent consideration liabilities at their estimated fair value, including accretion for the passage of time as well as adjustments to the liabilities’ fair values related to changes in the timing and/or probability of achieving milestones. The tables include contingent consideration liability adjustments in each respective historical period and do not include in future-period fair value changes, other than estimated accretion expense as determined at the end of the current quarter. These amounts are not taxable or tax deductible.
(2) Foreign exchange gains and losses are related to marking non-U.S. dollar contingent consideration to period-end exchange rates. The tables include foreign currency exchange loss or gain recorded in each respective historical period and do not include forecasted currency fluctuations in future periods. These gains and losses are not taxable or tax deductible.
(3) Amortization of acquisition-related intangible assets and associated tax impact. A significant portion of the acquisition-related amortization is not tax deductible.
(4) Represents the gain recognized on the sale of a strategic investment which was not tax-affected as it was offset by previously recognized capital losses.
(5) Income tax expense from the re-measurement of net deferred tax assets recognized after the enactment of the Tax Cuts and Jobs Act in December 2017.
(6) Represents an estimated royalty-related customer claim settlement accrued in the second quarter of fiscal 2018 and associated tax impact.
(7) Represents the acquisition of the Embolitech in-process research and development assets during the third quarter of fiscal 2018 and associated tax impact.
(8) Impairment of indefinite-lived intangible assets which were not tax deductible.
(9) Options to purchase common stock as well as unvested restricted stock and performance stock units are considered to be potentially dilutive common shares but have been excluded from the calculation of GAAP net loss per share as their effect is anti-dilutive for three months and year ended September 30, 2018 as a result of the net loss for those periods on a GAAP basis. However, as the Non-GAAP adjustments result in Non-GAAP net income, the dilutive effect of these options and other outstanding stock awards have been included in the calculation of Non-GAAP earnings per share. Accordingly, Diluted EPS includes these adjustments.
(10) Net (loss) income includes the effect of the above adjustments on the income tax provision, taking into account deferred taxes and non-deductible items. Effective rates of 24.5% (fiscal 2018) and between 34-35% (fiscal 2017) were used to estimate the income tax impact of the adjustments, except that expenses occurring in Ireland have not been tax-affected as all tax benefits are offset by a full valuation allowance and acquired in-process research and development, which will be deductible at a 21% statutory tax rate.

Source: Surmodics, Inc.

Surmodics, Inc.
Tim Arens, 952-500-7000
ir@surmodics.com